Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002736 (
amyotrophic lateral sclerosis
)
19,048
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Among the extensively occurring adenosine to inosine (A-to-I) conversions in RNA, RNA editing at the GluR2 Q/R site is crucial for the survival of mammalian organisms. Editing at this site is incomplete in the motor neurons of patients with sporadic
amyotrophic lateral sclerosis
(
ALS
). Adenosine deaminase acting on RNA type 2 (ADAR2) specifically mediates GluR2 Q/R site-editing, hence, it is likely a molecule relevant to the pathogenesis of sporadic
ALS
. Since no other transcript with ADAR2-mediated A-to-I positions is abundantly expressed in most neurons, the editors at the newly identified A-to-I positions were investigated.
CYFIP2
and FLNA mRNAs were identified together with mRNAs having known ADAR2-mediated editing positions in ADAR2-immunoprecipitates of the human cerebellum, indicating that these mRNAs probably possessed ADAR2-mediated positions. Furthermore, an in vitro RNAi knockdown system demonstrated that the
CYFIP2
mRNA K/E site and the BLCAP mRNA Y/C site were edited predominantly by ADAR2 and ADAR1, respectively.
CYFIP2
mRNA was ubiquitously expressed and particularly abundant in the central nervous system. The extent of
CYFIP2
K/E site-editing was between 30% and 80% in the central nervous system. Therefore, the extent of
CYFIP2
K/E site-editing may be an additional marker for ADAR2 activity in neuronal and other types of cells in vivo, as well as in vitro, and thus is considered to be a good tool for sporadic
ALS
research.
...
PMID:Newly identified ADAR-mediated A-to-I editing positions as a tool for ALS research. 1897 34